Determination That SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER (Sodium Chloride), Injectable, 234 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 89470-89471 [2016-29674]
Download as PDF
89470
Federal Register / Vol. 81, No. 238 / Monday, December 12, 2016 / Notices
requirements prior to the dispensing of
certain hearing aid devices to
individuals 18 years of age and older.
This guidance applies to the subset of
hearing aids that are regulated as class
I air-conduction hearing aids under
§ 874.3300(b)(1) (21 CFR 874.3300(b)(1))
and class II wireless air-conduction
hearing aids under § 874.3305, where
hearing aid means ‘‘any wearable
instrument or device designed for,
offered for the purpose of, or
represented as aiding persons with or
compensating for, impaired hearing,’’ as
defined in § 801.420(a)(1). This
guidance does not apply to class II boneconduction hearing aids as identified in
§ 874.3300(b)(2). Also, hearing aids
labeled for prescription use only, e.g.,
those that are inserted deep in the ear
canal by a hearing health professional,
should continue to be sold only as
directed.
This guidance is being implemented
without prior public comment because
the Agency has determined that prior
public participation is not feasible or
appropriate (see section 701(h)(1)(C)(i)
of the FD&C Act (21 U.S.C.
371(h)(1)(C)(i)) and § 10.115.(g)(2) (21
CFR 10.115(g)(2))). FDA believes that
immediate implementation of the
guidance is needed to assist in
addressing a significant public health
issue. Further, FDA has determined that
this guidance document presents a less
burdensome policy that is consistent
with public health. Although this
guidance is immediately in effect, FDA
will consider all comments received and
revise the guidance document as
appropriate.
mstockstill on DSK3G9T082PROD with NOTICES
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (§ 10.115). The
guidance represents the current thinking
of FDA on conditions for sale for airconduction hearing aids. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
VerDate Sep<11>2014
18:59 Dec 09, 2016
Jkt 241001
of ‘‘Immediately in Effect Guidance
Document: Conditions for Sale for AirConduction Hearing Aids’’ may send an
email request to CDRH-Guidance@
fda.hhs.gov to receive an electronic
copy of the document. Please use the
document number 16041 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 807, subpart E have been
approved under OMB control number
0910–0120; and the collections of
information in 21 CFR part 801 have
been approved under OMB control
number 0910–0485.
Dated: December 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–29724 Filed 12–9–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–P–1363]
Determination That SODIUM
CHLORIDE 23.4% IN PLASTIC
CONTAINER (Sodium Chloride),
Injectable, 234 Milligrams/Milliliter,
Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) has
determined that SODIUM CHLORIDE
23.4% IN PLASTIC CONTAINER
(sodium chloride), injectable, 234
milligrams (mg)/milliliter (mL), was not
withdrawn from sale for reasons of
safety or effectiveness. This
determination will allow FDA to
approve abbreviated new drug
applications (ANDAs) for sodium
chloride, injectable, 234 mg/mL, if all
other legal and regulatory requirements
are met.
FOR FURTHER INFORMATION CONTACT:
David Faranda, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213,
Silver Spring, MD 20993–0002, 301–
796–8767.
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength and
dosage form as the ‘‘listed drug,’’ which
is a version of the drug that was
previously approved. ANDA applicants
do not have to repeat the extensive
clinical testing otherwise necessary to
gain approval of a new drug application
(NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (§ 314.161 (21 CFR 314.161)).
FDA may not approve an ANDA that
does not refer to a listed drug.
SODIUM CHLORIDE 23.4% IN
PLASTIC CONTAINER (sodium
chloride), injectable, 234 mg/mL, is the
subject of NDA 019329, held by Abraxis
Pharmaceutical Products, and initially
approved on April 22, 1987. SODIUM
CHLORIDE 23.4% IN PLASTIC
CONTAINER is indicated for use in
patients who have special problems of
sodium electrolyte intake or excretion,
and for the treatment of sodium chloride
and water deficiencies, which
commonly occur in many diseases.
In a letter dated January 18, 1996, the
original NDA holder, Fujisawa USA,
Inc., notified FDA that SODIUM
CHLORIDE 23.4% IN PLASTIC
CONTAINER (sodium chloride),
injectable, 234 mg/mL, was being
discontinued, and FDA moved the drug
product to the ‘‘Discontinued Drug
SUPPLEMENTARY INFORMATION:
E:\FR\FM\12DEN1.SGM
12DEN1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 238 / Monday, December 12, 2016 / Notices
Product List’’ section of the Orange
Book.
Gordon Johnston Regulatory
Consultants, LLC, submitted a citizen
petition dated May 25, 2016 (Docket No.
FDA–2016–P–1363), under 21 CFR
10.30, requesting that the Agency
determine whether SODIUM CHLORIDE
23.4% IN PLASTIC CONTAINER
(sodium chloride), injectable, 234 mg/
mL, was withdrawn from sale for
reasons of safety or effectiveness.
After considering the citizen petition
and reviewing Agency records and
based on the information we have at this
time, FDA has determined under
§ 314.161 that SODIUM CHLORIDE
23.4% IN PLASTIC CONTAINER
(sodium chloride), injectable, 234 mg/
mL, was not withdrawn for reasons of
safety or effectiveness. The petitioner
has identified no data or other
information suggesting that SODIUM
CHLORIDE 23.4% IN PLASTIC
CONTAINER (sodium chloride),
injectable, 234 mg/mL, was withdrawn
for reasons of safety or effectiveness. We
have carefully reviewed our files for
records concerning the withdrawal of
SODIUM CHLORIDE 23.4% IN
PLASTIC CONTAINER (sodium
chloride), injectable, 234 mg/mL, from
sale. We have also independently
evaluated relevant literature and data
for possible postmarketing adverse
events. We have reviewed the available
evidence and determined that this drug
product was not withdrawn from sale
for reasons of safety or effectiveness.
Accordingly, the Agency will
continue to list SODIUM CHLORIDE
23.4% IN PLASTIC CONTAINER
(sodium chloride), injectable, 234 mg/
mL, in the ‘‘Discontinued Drug Product
List’’ section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. ANDAs that refer
to this drug product may be approved
by the Agency as long as they meet all
other legal and regulatory requirements
for the approval of ANDAs. If FDA
determines that labeling for this drug
product should be revised to meet
current standards, the Agency will
advise ANDA applicants to submit such
labeling.
Dated: December 7, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–29674 Filed 12–9–16; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
18:59 Dec 09, 2016
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Ebola Virus Disease Vaccines—
Amendment
Notice of Amendment to the
December 3, 2014, Declaration under
the Public Readiness and Emergency
Preparedness Act for Ebola Virus
Disease Vaccines.
ACTION:
The Secretary is amending the
Declaration issued pursuant to section
319F–3 of the Public Health Service Act
on December 3, 2014 (79 FR 73314) and
amended on December 1, 2015 (80 FR
76541) to extend the effective time
period for an additional 24 months and
to clarify the description of Covered
Countermeasures consistent with the
terms of the Declaration and
republishing the Declaration in its
entirety as amended.
DATES: The Amended Declaration is
effective as of December 3, 2016.
FOR FURTHER INFORMATION CONTACT:
Nicole Lurie, MD, MSPH, Assistant
Secretary for Preparedness and
Response, Office of the Secretary,
Department of Health and Human
Services, 200 Independence Avenue
SW., Washington, DC 20201, Telephone
202–205–2882.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services to issue a Declaration to
provide liability immunity to certain
individuals and entities (Covered
Persons) against any claim of loss
caused by, arising out of, relating to, or
resulting from the administration or use
of medical countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration. Using this authority, the
Secretary is amending the Declaration
that provides liability immunity to
Covered Persons for activities related to
the Covered Countermeasures, Ebola
Virus Disease Vaccines listed in Section
VI of the Declaration, to extend the
effective time period for an additional
24 months and to clarify the description
of Covered Countermeasures consistent
with the terms of this Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, Division C, Section 2. It amended
the Public Health Service (PHS) Act,
adding section 319F–3, which addresses
liability immunity, and section 319F–4,
SUMMARY:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
89471
which creates a compensation program.
These sections are codified in the U.S.
Code as 42 U.S.C. 247d–6d and 42
U.S.C. 247d–6e, respectively.
The Pandemic and All-Hazards
Preparedness Reauthorization Act
(PAHPRA), Public Law 113–5, was
enacted on March 13, 2013. Among
other things, PAHPRA added sections
564A and 564B to the Federal Food,
Drug, and Cosmetic (FD&C) Act to
provide new authorities for the
emergency use of approved products in
emergencies and products held for
emergency use. PAHPRA accordingly
amended the definitions of ‘‘Covered
Countermeasures’’ and ‘‘qualified
pandemic and epidemic products’’ in
section 319F–3 of the Public Health
Service Act (PREP Act provisions), so
that products made available under
these new FD&C Act authorities could
be covered under PREP Act
Declarations. PAHPRA also extended
the definition of qualified pandemic and
epidemic products that may be covered
under a PREP Act Declaration to include
products or technologies intended to
enhance the use or effect of a drug,
biological product, or device used
against the pandemic or epidemic or
against adverse events from these
products.
The Ebola virus causes an acute,
serious illness that is often fatal. From
2014 to 2015, West Africa experienced
the largest and most complex Ebola
outbreak since the virus was discovered
in 1976, affecting populations in West
African countries and travelers who left
West Africa. In 2014, the World Health
Organization (WHO) declared the Ebola
Virus Disease Outbreak as a Public
Health Emergency of International
Concern under the framework of the
International Health Regulations (2005).
In March 2016, WHO determined that
the Ebola outbreak no longer constituted
a Public Health Emergency of
International Concern, but emphasized
the crucial need for continued support
to prevent, detect and respond rapidly
to any new Ebola outbreak in West
Africa. Thus, there is a continuing need
for development of vaccines against
Ebola Virus Disease.
Unless otherwise noted, all statutory
citations below are to the U.S. Code.
Section I, Determination of Public
Health Emergency or Credible Risk of
Future Public Health Emergency
Before issuing a Declaration under the
PREP Act, the Secretary is required to
determine that a disease or other health
condition or threat to health constitutes
a public health emergency or that there
is a credible risk that the disease,
condition, or threat may constitute such
E:\FR\FM\12DEN1.SGM
12DEN1
Agencies
[Federal Register Volume 81, Number 238 (Monday, December 12, 2016)]
[Notices]
[Pages 89470-89471]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-29674]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-P-1363]
Determination That SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
(Sodium Chloride), Injectable, 234 Milligrams/Milliliter, Was Not
Withdrawn From Sale for Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER (sodium
chloride), injectable, 234 milligrams (mg)/milliliter (mL), was not
withdrawn from sale for reasons of safety or effectiveness. This
determination will allow FDA to approve abbreviated new drug
applications (ANDAs) for sodium chloride, injectable, 234 mg/mL, if all
other legal and regulatory requirements are met.
FOR FURTHER INFORMATION CONTACT: David Faranda, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213, Silver Spring, MD 20993-0002, 301-
796-8767.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength and dosage form as the ``listed drug,'' which is a version of
the drug that was previously approved. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER (sodium chloride),
injectable, 234 mg/mL, is the subject of NDA 019329, held by Abraxis
Pharmaceutical Products, and initially approved on April 22, 1987.
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER is indicated for use in
patients who have special problems of sodium electrolyte intake or
excretion, and for the treatment of sodium chloride and water
deficiencies, which commonly occur in many diseases.
In a letter dated January 18, 1996, the original NDA holder,
Fujisawa USA, Inc., notified FDA that SODIUM CHLORIDE 23.4% IN PLASTIC
CONTAINER (sodium chloride), injectable, 234 mg/mL, was being
discontinued, and FDA moved the drug product to the ``Discontinued Drug
[[Page 89471]]
Product List'' section of the Orange Book.
Gordon Johnston Regulatory Consultants, LLC, submitted a citizen
petition dated May 25, 2016 (Docket No. FDA-2016-P-1363), under 21 CFR
10.30, requesting that the Agency determine whether SODIUM CHLORIDE
23.4% IN PLASTIC CONTAINER (sodium chloride), injectable, 234 mg/mL,
was withdrawn from sale for reasons of safety or effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
(sodium chloride), injectable, 234 mg/mL, was not withdrawn for reasons
of safety or effectiveness. The petitioner has identified no data or
other information suggesting that SODIUM CHLORIDE 23.4% IN PLASTIC
CONTAINER (sodium chloride), injectable, 234 mg/mL, was withdrawn for
reasons of safety or effectiveness. We have carefully reviewed our
files for records concerning the withdrawal of SODIUM CHLORIDE 23.4% IN
PLASTIC CONTAINER (sodium chloride), injectable, 234 mg/mL, from sale.
We have also independently evaluated relevant literature and data for
possible postmarketing adverse events. We have reviewed the available
evidence and determined that this drug product was not withdrawn from
sale for reasons of safety or effectiveness.
Accordingly, the Agency will continue to list SODIUM CHLORIDE 23.4%
IN PLASTIC CONTAINER (sodium chloride), injectable, 234 mg/mL, in the
``Discontinued Drug Product List'' section of the Orange Book. The
``Discontinued Drug Product List'' delineates, among other items, drug
products that have been discontinued from marketing for reasons other
than safety or effectiveness. ANDAs that refer to this drug product may
be approved by the Agency as long as they meet all other legal and
regulatory requirements for the approval of ANDAs. If FDA determines
that labeling for this drug product should be revised to meet current
standards, the Agency will advise ANDA applicants to submit such
labeling.
Dated: December 7, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-29674 Filed 12-9-16; 8:45 am]
BILLING CODE 4164-01-P